Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News


December 17, 2021 in Arbor Rapha Capital BioHoldings Corp I, Portfolio, Rapha Capital Management

Arbor Rapha Capital Bioholdings Corp. I Announces the Separate Trading of its Shares of Class A Common Stock and Redeemable Warrants Commencing December 20, 2021

NEW YORK, NY, December 17, 2021 — Arbor Rapha Capital Bioholodings Corp. I (NASDAQ: ARCKU) (the “Company”) today announced that, commencing…
Read More
December 14, 2021 in DELiver Therapeutics, Portfolio, Rapha Capital Management

Rapha Capital BioVentures Fund I Launches DELIVER Therapeutics Inc. with $3 Million Convertible Note Financing

Company applying novel, high-throughput screening technologies to DELIVER therapeutics that address the most difficult problems in clinical medicine  Rapha Capital BioVentures Fund…
Read More
December 8, 2021 in FIZE Medical Ltd, Portfolio, Rapha Capital Management

FIZE Medical Raises $4 Million Series A-1 Financing

FIZE Medical Ltd. FIZE an innovative provider of data derived from monitoring real-time urine output, announced today the closing of…
Read More